Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Daily

Download Data

Edgewise Therapeutics Inc Share Price on June 03, 2024: USD 17.41

Edgewise Therapeutics Inc Share Price is USD 17.41 on June 03, 2024, a 85.41% change year over year. Share price refers to the current trading price of a single share of a company's stock. It represents the monetary value that investors are willing to pay for ownership in the company. Share prices are determined by the supply and demand dynamics in the stock market and can fluctuate throughout the trading day. Changes in share prices are influenced by various factors, including company performance, industry trends, market conditions, investor sentiment, and economic indicators. Share price is a key indicator used by investors to assess the performance and valuation of a company's stock.

Edgewise Therapeutics Inc 52-week high Share Price is USD 21.23 on May 07, 2024, which is 21.94% above the current Share Price.
Edgewise Therapeutics Inc 52-week low Share Price is USD 5.51 on November 10, 2023, which is -68.35% below the current Share Price.
Edgewise Therapeutics Inc average Share Price for the last 52 weeks is USD 11.12.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends